What Bioflorin Treats: Main Uses and Benefits

Bioflorin, which contains the active ingredient Enterococcus faecium strain SF68, contributes to supporting functional stability within the gut microflora. This is commonly used to help manage various conditions presenting with systemic or localized discomfort that affect the digestive system.

The primary therapeutic areas of use are focused on providing support for the functional stability of the gut microflora, which is considered relevant in contexts involving heightened systemic burden. The preparation is indicated for addressing acute symptomatic relief for non-specific diarrhea, enteritis, and enterocolitis. It may also assist with managing symptoms linked to situations where the intestinal flora (dysbiosis) has become affected by factors such as antibiotic therapy or changes in diet.

By supplying the gut with the living SF68 strain, Bioflorin may assist with managing symptoms related to inflammatory or irritative states and assists with maintaining functional stability when symptoms are more noticeable. This contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

1. Swissmedic-Approved Indication Summary

Who Can and Cannot Use Bioflorin?

The eligibility for using Bioflorin, which contains Enterococcus faecium SF68, is defined by specific rules documented in official regulatory labeling. Use is generally permitted for adults and children over 12 years of age.

---

Absolute Contraindications

The medicine must not be used by individuals with known hypersensitivity or allergy to the active substance or any other ingredient. A strict contraindication applies to patients with disorders of the immune system resulting in immunosuppression, such as in cases of HIV infection.

---

Restricted and Conditional Use

Certain populations require specific medical consultation before use:

• Children from 2 to 12 years of age must only use Bioflorin under the guidance of a physician. Use is not explicitly established for children under 2 years.
• Patients with autoimmune diseases or existing serious gastrointestinal diseases (including Crohn's disease, ulcers, and tumors) are restricted from standard use and require medical advice.
• Individuals with a known lactose or sugar intolerance must consult a doctor, as the product contains lactose.

---

Pregnancy and Lactation

Official documentation states that application is generally possible during pregnancy and breastfeeding, although a doctor must make the final decision regarding use while pregnant.

Interactions with other medicines and products

This section summarizes the officially documented interaction patterns for Bioflorin, based strictly on government regulatory product information.

The interaction profile primarily involves co-administered agents that affect the viability of the medicine's live microbial cultures, requiring specific timing separation or formal restrictions.

---

Official Interaction Structure

Category	Documented Interacting Agent	Official Regulatory Requirement
Contraindicated Combination	Oral Live Vaccines (e.g., typhoid fever vaccine)	Co-administration is formally contraindicated (must not be taken together).
Exposure-Altering Agent	Antibiotics (Oral)	Documented to reduce the effect of the live culture preparation.
Timing Restriction	Antibiotics (Oral)	Must be administered at an interval of at least 2 hours from the intake of oral antibiotics.

---

Regulatory Summary

The regulatory documents define the product’s interaction structure through two specific constraints. The first is a formal restriction prohibiting co-administration with oral live vaccines due to the potential for microbial interference. The second establishes a mandatory timing separation rule for use with oral antibiotics. This separation is required because antibiotics are officially documented to reduce the effect of the live microbial culture preparation, which is the core functional component of Bioflorin.

Competitive Exclusion and pH Regulation

The mechanism initiates in the intestinal lumen where the active strain, Enterococcus Faecium SF68, engages in competitive exclusion by occupying adhesion sites on the epithelial lining and utilizing nutrients, limiting the proliferation of undesirable microbial strains. The bacteria also ferment carbohydrates to produce Lactic Acid and Short-Chain Fatty Acids (SCFAs). This secretory action lowers the intestinal pH, creating an environment chemically antagonistic to many opportunistic bacteria, contributing to the regulation of the gut ecosystem's microbial composition.

---

️ Metabolic Delivery for Barrier Integrity

A key downstream effect of this mechanism involves the delivery of metabolic fuel to the host's cells. The secreted SCFAs function as the primary energy source for the enterocytes (gut lining cells). This metabolic activity maintains the structural integrity and functional capacity of the intestinal barrier. This consequence limits the molecular transit of luminal substances across the mucosal surface.

---

️ Localized Immunomodulation

The mechanism also involves local immune system regulation through the production of the enzyme Arginine Deiminase (ADI) by SF68. This biological target engages the host's mucosal immune pathways, specifically dampening the activation of key pro-inflammatory signaling pathways like NF-kappaB. The suppression of this molecular cascade modulates localized pro-inflammatory signaling within the gut wall, influencing the immune response state at the mucosal surface.

How to Use Bioflorin

Bioflorin capsules are administered orally, and standardized instructions detail the specific dosage and administration procedures based on age to ensure correct use of the medicine, with an average duration of use of 5–7 days, which may be prolonged after consulting a physician.

Official Dosing and Administration

Age Group	Standard Dosage	Frequency	Preparation Notes
Adults	1 capsule	3 times daily	Take with some liquid.
Children (2–12 years)	1 capsule	2 times daily	Take with some liquid.
Infants / Young Children	1–2 capsules	Daily	Capsule contents may be dispersed in liquid (milk, water, fruit juice) for easier intake.

The dose may be increased according to the severity of the clinical condition, based on medical evaluation. For prophylactic use (e.g., travel), the recommended dose is typically 2 capsules daily for adults, children, and infants.

Procedural and Timing Rules

• Liquid Temperature: When taking the capsule or dispersing the contents, the liquid used must not be hot to avoid compromising the active ingredient.
• Missed Dose: If a dose is missed, it is advised not to take a double amount to make up for the forgotten dose.
• Drug Interactions: If the patient is simultaneously taking oral antibiotics, the Bioflorin capsule must be taken at an interval of 2 hours from the antibiotic. Bioflorin should also not be taken at the same time as oral vaccinations.

These instructions define the standardized procedure for using Bioflorin, ensuring the active organisms are viable upon administration and that the product is used in a manner that adheres to the established conditions for the product's use.

Research evidence / Overview of studies for Bioflorin

Evidence for Use in Acute Diarrhea, Enteritis, and Enterocolitis

Research has examined the E. faecium SF68 strain in conditions characterized by acute or disruptive episodes, such as non-specific acute diarrhea, enteritis, and enterocolitis. Researchers conducted short-term, randomized controlled trials (RCTs) and other comparative studies to assess this use. These studies monitored patient-reported outcomes describing perceived discomfort and aimed to measure changes in acute symptoms and their time course in the observed populations, with the main outcome being the time until the resolution of diarrhea. Studies reported patterns where the measured time to diarrhea resolution was numerically tracked in the E. faecium SF68 group and compared to control groups. The evidence level for Bioflorin is graded as moderate to low in scientific reviews depending on the indication.

---

Evidence for Preventing Antibiotic-Associated Diarrhea (AAD)

Research examined the E. faecium SF68 strain in the context of diarrhea associated with antibiotic treatment. Studies utilized randomized, double-blind, placebo-controlled trials that monitored the incidence rate (the percentage of patients) who experienced diarrhea during or immediately after taking antibiotics. The findings describe patterns observed in the studies, where the measured incidence of AAD was observed in some studies to track with a difference in rate between the group receiving the SF68 strain and the placebo group. The data for certain groups remain limited, as the follow-up durations were restricted to the antibiotic exposure period.

---

Durability of Effect, Limitations, and Different Patient Groups

Research exploring short-term symptom changes has typically involved follow-up durations that were limited to the acute treatment phase; long-term effects are not fully established. The primary clinical trials included specific age groups, predominantly adults and school-aged children, and data for groups such as very young infants or pregnant individuals remain scarce. Key limitations cited in scientific literature include the finding that sample sizes were modest in some trials and that follow-up durations were consistently short.

Key Studies & References

1. Enterococcus faecium SF68: Safety, efficacy and clinical use in diarrhea-related indications
2. Compendium.ch: Summary of Product Characteristics (Bioflorin)

Common questions about Bioflorin (FAQ)

Q: How quickly should I expect Bioflorin to start working?

Studies have examined the time until symptoms resolve when using Bioflorin for acute diarrhea. Findings describe patterns where the time to resolution was numerically tracked as shorter in the group receiving the active ingredient. For example, some trials reported a median time to symptom resolution of 3 days, compared to control groups.

Q: What is the difference between Bioflorin and other common supplements?

Bioflorin is described in official regulatory documents as a licensed pharmaceutical preparation, which helps distinguish it from common, non-regulated dietary supplements. This classification means the product adheres to specific governmental regulatory standards for product quality and classification, rather than standards for food products.

Q: Are there any long-term side effects associated with Bioflorin?

Most clinical trials supporting the product's use had short-term follow-up periods, often limited to the acute treatment phase (e.g., 7 days). Consequently, long-term effects or safety monitoring beyond the acute treatment period are not fully established in the core regulatory evidence.

Q: Why do people sometimes feel bloated when starting Bioflorin?

It is observed that some individuals may experience an increase in stomach gas or a feeling of bloating when they first begin using a product containing live microbial cultures. This digestive symptom is sometimes reported when first starting products of this type and is generally observed to be temporary.

Q: Are there any known food or drink restrictions when using Bioflorin?

Official administration rules include one specific restriction: the liquid used to take the capsule or disperse its contents should not be hot. The active ingredients are sensitive to temperatures above 40^circC and may be rapidly compromised by heat. No other general food or drink restrictions are officially documented.

Q: How long after starting Bioflorin can I stop taking it?

Regulatory documents state that the average duration of treatment is 5–7 days. If the symptoms persist after this period or the expected results do not occur, official instructions indicate that a medical consultation is required.

Q: Why is Bioflorin sometimes recommended after taking antibiotics?

The product is officially indicated for addressing an imbalance of intestinal flora (dysmicrobism) that is often caused by antibiotics. Research has also examined the strain's use for the prevention of antibiotic-associated diarrhea (AAD).

Q: Is it okay to take Bioflorin every day?

Dosing information provided in regulatory documents is specified for short-term, acute treatment, with an average duration of 5–7 days. Use of the product for continuous, long-term daily intake beyond this period is often managed through consultation with a physician.

Q: What is the shelf life of Bioflorin?

Official product information specifies two time limits: the product should not be used after the expiry date printed on the carton. Additionally, once the container is first opened, the contents must be used within four weeks.

Q: Is there a maximum time limit for using Bioflorin?

Official dosing instructions are provided for an average duration of 5–7 days. While regulatory documents state that the duration of use may be prolonged only after consulting a physician, an explicit regulatory maximum time limit is not formally defined.

Q: Does Bioflorin affect the immune system?

Official safety notes state the product is strictly contraindicated for use in individuals with certain disorders of the immune system that result in immunosuppression. This restriction is related to the theoretical risk of systemic infection when administering live microbial cultures to these patients.

Q: Does Bioflorin contain any common allergens like gluten or soy?

Official excipient lists confirm that the product contains lactose. The presence of lactose in the product may necessitate caution for individuals with a known sugar intolerance. The official safety warnings do not address the presence or absence of other common allergens like gluten or soy.

Q: Can Bioflorin be used to prevent certain conditions?

The official indications, as defined in regulatory documents, state that Bioflorin is used for the prevention of specific diarrheal conditions. This includes prevention of traveler’s diarrhea and antibiotic-associated diarrhea (AAD).

Q: Are the reported side effects generally mild?

The reported side effects of Bioflorin are classified by frequency and severity. Common effects like gas are observed, but rare, and more critical systemic reactions, such as a hypersensitivity (allergic) reaction, are also officially documented.

Q: What happens if Bioflorin is exposed to heat?

The active ingredient in the product, the Enterococcus faecium SF68 strain, is highly sensitive to heat. According to the official product information, exposure to temperatures above 40^circC leads to the rapid inactivation of the live cultures, compromising the product’s function.

Q: Can men and women use Bioflorin in the same way?

Regulatory documents provide dosage and administration instructions based strictly on the user's age group, such as adults, children, and infants. These official instructions do not contain any distinction or difference in use based on gender.

How to Store and Dispose of Bioflorin

Bioflorin must be stored according to specific regulatory requirements to maintain the viability of the live microbial cultures.

Storage Conditions and Stability

The medicine must not be stored above 25°C to prevent the rapid inactivation of the active strain. It is required to keep the product in the original outer carton for protection from light and moisture.

The container must be kept out of the reach of children. Once the container is first opened, the product must be used within four weeks.

Disposal Instructions

Unused or expired Bioflorin must be disposed of according to local regulations. Medicines should not be thrown away via wastewater or household waste; they should be returned to designated pharmacies or collection points.